Meeting NewsVideo

VIDEO: New NLA president discusses updates to PCSK9 inhibitor recommendations

PHILADELPHIA — In this Cardiology Today video exclusive, James A. Underberg, MD, MS, FACPM, FACP, FNLA, new president of the National Lipid Association, discusses the NLA’s updated recommendations for the use of PCSK9 inhibitors.

According to Underberg, who is also clinical assistant professor of medicine at the NYU School of Medicine, the decision to provide an update to the association’s previous recommendations came in part from the recent clinical data from the FOURIER trial and the GLAGOV trial, as well as newly accumulated efficacy data regarding various patient groups.

The NLA made recommendations for patients with atherosclerotic CVD — who were divided by whether their condition was stable or progressive — patients with familial hypercholesterolemia and those with statin intolerance.

“While statin intolerance is not part of the label for PCSK9 inhibitors, we do feel that there may be a role for the utilization of PCSK9 inhibitors in patients who have increased CV risk, specifically those with atherosclerotic CVD or those with familial hypercholesterolemia who cannot tolerate statins,” Underberg said.

For more information on the recent publication of these updates, visit www.lipidjournal.com or www.lipid.org.

PHILADELPHIA — In this Cardiology Today video exclusive, James A. Underberg, MD, MS, FACPM, FACP, FNLA, new president of the National Lipid Association, discusses the NLA’s updated recommendations for the use of PCSK9 inhibitors.

According to Underberg, who is also clinical assistant professor of medicine at the NYU School of Medicine, the decision to provide an update to the association’s previous recommendations came in part from the recent clinical data from the FOURIER trial and the GLAGOV trial, as well as newly accumulated efficacy data regarding various patient groups.

The NLA made recommendations for patients with atherosclerotic CVD — who were divided by whether their condition was stable or progressive — patients with familial hypercholesterolemia and those with statin intolerance.

“While statin intolerance is not part of the label for PCSK9 inhibitors, we do feel that there may be a role for the utilization of PCSK9 inhibitors in patients who have increased CV risk, specifically those with atherosclerotic CVD or those with familial hypercholesterolemia who cannot tolerate statins,” Underberg said.

For more information on the recent publication of these updates, visit www.lipidjournal.com or www.lipid.org.

    See more from National Lipid Association Scientific Sessions